North America Liver Disease Diagnostics Market By End User (Hospitals, Laboratories and Other End Users), By Diagnosis Technique (Imaging, Biopsy, Endoscopy, Laboratory tests and Other Diagnosis Techniques), By Country, Industry Analysis and Forecast, 2020 - 2026
Special Offering: Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support
Get in-depth analysis of the COVID-19 impact on the North America Liver Disease Diagnostics Market
Market Report Description
The North America Liver Disease Diagnostics Market would witness market growth of 5.8% CAGR during the forecast period (2020-2026). Liver transplantation is the second most common organ transplant in the world after liver transplant. However, less than 10% of the global demands for organ transplantation are being met at the current rate of transplantation. While these numbers are sobering, they provide a significant incentive to improve public health, considering that most causes of liver disease are preventable.
The contrast agent, gadoxetic acid, is administered into a peripheral vein. It is absorbed by the liver cells (hepatocytes) and removed by the bile ducts. Chronic inflammation of the liver tissue, such as viral hepatitis or fatty liver disease, may lead to scarring (fibrosis/cirrhosis) of the organ, leading to a reduction in the number of functioning hepatocytes and/or a decrease in the number of cellular transporters responsible for the absorption of the contrast agent into hepatocytes. It ultimately leads to a decreased reduction of the liver as a contrast agent. Radiation-free fMRI shows damage to the liver cell as decreased liver light and impaired excretion of the contrast agent in the bile ducts by serial imaging.
North America dominated the market in the regional market. High investment in R&D and the involvement of key players are expected to be responsible for the growth of the liver disease diagnostics market in the region. In addition, the existence of organizations offering information on the treatment of diseases to patients is expected to drive the growth of the liver disease diagnostics industry. One such agency is GetPalliativeCare.org, which provides information on palliative care related to medical procedures such as endoscopy, CT scan, and biopsy.
Based on End User, the market is segmented into Hospitals, Laboratories and Other End Users. Based on Diagnosis Technique, the market is segmented into Imaging, Biopsy, Endoscopy, Laboratory tests and Other Diagnosis Techniques. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
Free Valuable Insights: Liver Disease Diagnostics Market in North America is expected to register a CAGR of 5.8% during the forecast period (2020-2026)
The market research report covers theanalysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, F. Hoffmann-La Roche Ltd., Boston Scientific Corporation, Siemens AG (Siemens Healthineers), Bayer AG, Merck & Co., Inc., Sanofi S.A., Novartis AG, Pfizer, Inc., and Randox laboratories limited.
Scope of the North America Liver Disease Diagnostics Market Analysis
Market Segmentation:
By End-User
- Hospitals, Laboratories and Other End Users
By Diagnosis Technique
- Imaging
- Biopsy
- Endoscopy
- Laboratory tests and
- Other Diagnosis Techniques
- Assisted Reproductive Technology & Varicocele Surgery
- Medication
By Country
- US
- Canada
- Mexico
- Rest of North America
Companies Profiled
- Abbott Laboratories
- Hoffmann-La Roche Ltd.
- Boston Scientific Corporation
- Siemens AG (Siemens Healthineers)
- Bayer AG
- Merck & Co., Inc.
- Sanofi S.A.
- Novartis AG
- Pfizer, Inc.
- Randox laboratories limited
Unique Offerings from KBV Research
- Exhaustive coverage
- Highest number of market tables and figures
- Subscription based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free